Trial Profile
A Single-Center, Prospective, Non-randomized Study Investigating the Long-Term Efficacy and Success Rate of Intravesical Electromotive Administration of Botulinum Toxin Type A (BoNTA) (Dysport) in Myelomeningocele (MMC) Patients who had Urinary Incontinence due to Neuropathic Detrusor Overactivity (NDO)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 08 Dec 2017 Results published in the Urology Journal.